Clinical effects of assessing electronic patient-reported outcomes monitoring symptomatic toxicities during breast cancer therapy: a nationwide and population-based study.
Adverse events
Breast cancer
Chemotherapy
Patient-reported outcome
Symptomatic toxicities
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
12
11
2020
accepted:
01
04
2021
pubmed:
11
4
2021
medline:
11
1
2022
entrez:
10
4
2021
Statut:
ppublish
Résumé
The involvement of cancer patients in symptom reporting talks into our cultural narrative of empowerment and participation in decisions in health of both patients and professionals. Electronic patient-reported outcome (ePRO) is a tool applied for use in such interaction. Based on limited evidence and few empirical studies, health systems are rapidly implementing this instrument in managing patients in active treatment and in follow-up. In a cluster randomized trial of all Danish oncology departments treating breast cancer with adjuvant chemotherapy, we applied ePRO in 347 patients consecutively recruited. Our primary outcome, which was at least one treatment adjustment, was not significantly influenced using ePRO, 34% in the ePRO arm and 41% in the usual care arm received at least one treatment adjustment, p = 0.095. Number of hospitalizations and events of febrile neutropenia were not influenced by the intervention. We believe that one of the main reasons for this finding could be the application of PRO in a well-regulated treatment setting within a public health care system where the most impacting symptomatic toxicities are already taken care off.Trial registration: Clinicaltrials.gov identifier: NCT02996201, registered 19 Dec 2016, retrospectively registered.
Identifiants
pubmed: 33837509
doi: 10.1007/s12282-021-01244-x
pii: 10.1007/s12282-021-01244-x
doi:
Substances chimiques
Antineoplastic Agents
0
Banques de données
ClinicalTrials.gov
['NCT02996201']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1096-1099Subventions
Organisme : Kræftens Bekæmpelse
ID : R113-A7084-14-S34
Informations de copyright
© 2021. The Japanese Breast Cancer Society.
Références
Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33(8):910–5.
doi: 10.1200/JCO.2014.57.9334
Falchook AD, Green R, Knowles ME, Amdur RJ, Mendenhall W, Hayes DN, et al. Comparison of patient-and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2016;142(6):517–23.
doi: 10.1001/jamaoto.2016.0656
Chera BS, Amdur RJ, Tepper J, Qaqish B, Green R, Aumer SL, et al. Phase 2 trial of De-intensified Chemoradiation therapy for favorable-risk human papillomavirus-sssociated oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(5):976–85.
doi: 10.1016/j.ijrobp.2015.08.033
Bruner DW, Movsas B, Basch E. Capturing the patient perspective: patient-reported outcomes as clinical trial endpoints. Am Soc Clin Oncol Educ Book. 2012;139–44. https://doi.org/10.14694/EdBook_AM.2012.32.80 .
Howell D, Molloy S, Wilkinson K, Green E, Orchard K, Wang K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26(9):1846–58.
doi: 10.1093/annonc/mdv181
Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197–8.
doi: 10.1001/jama.2017.7156
Denis F, Basch E, Septans AL, Bennouna J, Urban T, Dueck AC, et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA. 2019;321(3):306–7.
doi: 10.1001/jama.2018.18085
Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006;24(36):5664–71.
doi: 10.1200/JCO.2006.07.3916
Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, et al. Long-term follow-up of the E1199 phase III trial evaluating the role of Taxane and schedule in operable breast cancer. J Clin Oncol. 2015;33(21):2353–60.
doi: 10.1200/JCO.2015.60.9271
Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.
doi: 10.1093/jnci/dju244
Baeksted C, Nissen A, Pappot H, Bidstrup PE, Mitchell SA, Basch E, et al. Danish translation and linguistic validation of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Pain Symptom Manage. 2016;52(2):292–7.
doi: 10.1016/j.jpainsymman.2016.02.008
Pappot HBC, Knoop A, Mitchell SA, Nissen A, Johansen C. Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE). Breast J. 2019;25(2):269–72. https://doi.org/10.1111/tbj.13204 (Epub 2019 Feb 1).
doi: 10.1111/tbj.13204
pubmed: 30761667
Hjollund NH, Larsen LP, Biering K, Johnsen SP, Riiskjaer E, Schougaard LM. Use of patient-reported outcome (PRO) measures at group and patient levels: experiences from the generic integrated PRO system, West chronic. Interact J Med Res. 2014;3(1):e5.
doi: 10.2196/ijmr.2885
Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014;3:366.
doi: 10.1186/2193-1801-3-366
Enright K, Grunfeld E, Yun L, Moineddin R, Ghannam M, Dent S, et al. Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer. J Oncol Pract. 2015;11(2):126–32.
doi: 10.1200/JOP.2014.001073
Absolom K, Warrington L, Hudson E, et al. Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy. J Clin Oncol. 2021;39:734–47.
doi: 10.1200/JCO.20.02015